SLRX - Salarius Pharma Market Value

Graphic logo of Salarius (SLRX)

The market trend for Salarius Pharmaceuticals (SLRX), which reached the 0.01 level as shown on this chart, is driven by anticipation of targeted drug trial results, while current quotes already price in liquidity shortages and R&D costs. Price stability is supported by strict adherence to temperature controls during the transportation of test components. The business relies on epigenetic developments, creating LSD1 inhibitors to halt cell division in Ewing sarcoma.

SLRX (salariuspharma.com) Market Capitalization history from 07/04/2022 to 01/08/2026

Metric breakdowns and analytics for Salarius Pharma (SLRX)

Fundamental company valuation:Salarius Pharmaceuticals, Inc. SLRX
Product sample of Salarius Pharmaceuticals

Market capitalization dynamics serve as a fundamental benchmark for assessing market investment expectations. This indicator measures the company's total capital, reflecting a real-time reassessment of risks. Analyzing the issuer's total market value allows for the identification of a gap between infrequent reporting and market sentiment. Chart extremes signal a search for a compromise between potential returns and drawdown risk. For Salarius Pharmaceuticals (SLRX), the critical minimum confirms investor concerns regarding liquidity shortages and FDA regulatory barriers.

Competitors of Salarius Pharmaceuticals (SLRX)

Market Value BeiGene ONC|Halozyme Therapeutics, Inc. - Market Value|RVMD - Market Value|Market Value AAPG (Ascentage Pharma Corp)|CGON (CG Oncology, Inc.) - Market Valuation|Market Capitalization URGN|BCAX (Bicara Therapeutics) - Market Capitalization|Market Valuation Personalis Inc (PSNL)|Market Capitalization ERAS|Market Capitalization Delcath Corp (DCTH)|Market Value Y-mAbs Therapeutics YMAB|AURA: Market Capitalization|Candel - Market Capitalization|Accuray Inc (ARAY) - Market Valuation|SLS: Market Capitalization|Market Value Actuate Therapeutics Inc (ACTU)|Market Value Citius Oncology, Inc.|HURA: Market Value|Market Valuation TARA (Protara Therapeutics, Inc.)|FATE (Fate Therapeutics Inc) - Market Value|Market Capitalization WHWK (Aadi Bioscience)|TCRX - Market Valuation|CSBR: Market Valuation|XBIT - Market Capitalization|cel-sci.com (CVM) - Market Value|OS Therapies Inc. - Market Value|RADX (Radiopharm Theranostics) - Market Capitalization|Market Value Artiva ARTV|Market Value Adlai Nortye Ltd. (ANL)|Market Capitalization verupharma.com|Market Capitalization TPST (Tempest Therapeutics, Inc.)|Market Capitalization Xilio Therapeutics Inc XLO|RENB - Market Value|MURA: Market Value|KAPA: Market Capitalization|OnKure Therapeutics (OKUR) - Market Capitalization|Market Value CytoMed Therapeutics Ltd|CRIS: Market Value|Market Capitalization APLM|Market Capitalization Tharimmune Corporation|Advanced Biomed - Market Valuation|Market Capitalization genprex.com GNPX|CLDI - Market Value|Market Capitalization sunshinebiopharma.com SBFM|XBIO (xeneticbio.com) - Market Valuation|Kitov Pharma - Market Value|Market Value American Oncology Network Inc|beigene.com - Market Valuation|Market Capitalization CKPT|ELEV (Elevation Oncology Inc.) - Market Value|Market Capitalization ICAD (iCAD)|Market Capitalization Ikena Oncology Inc. IKNA|NTBL - Market Value|Market Value VIRX (Viracta Therapeutics)|MorphoSys (MOR) - Market Value|Market Valuation NAYA Biosciences Inc|AAPGV (Ascentage Pharma Group Ltd) - Market Capitalization